Topotecan in patients with advanced neuroendocrine tumors

A phase II study with significant hematologic toxicity

Stephen Maxted Ansell, Michelle R. Mahoney, Erin M. Green, Joseph Rubin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

New agents with antitumor activity in neuroendocrine tumors are sorely needed. We therefore conducted a phase II study of topotecan (TOPA) 1.5 mg/m2/d for 5 days every 3 weeks in 22 patients with advanced carcinoid and islet cell tumors. Severe neutropenia in 8 of 11 patients (72%) prompted a 30% dose reduction of TOPA to 1.05 mg/m2 for the final 11 patients enrolled. No objective responses were observed. Eighteen patients have progressed and 14 have died. The median time to progression was 4.2 months (95% CI: 2.9-6.5) and the median survival was 1.9 years (95% CI: 0.63-2.3). Hematologic adverse events were significant, with 16 of 22 patients developing grade IV neutropenia; however, there were no septic deaths. Nonhematologic adverse events were infrequent and were not dose limiting. In conclusion, further studies of this schedule of TOPA in this patient population are not recommended due to the lack of tumor response and significant hematologic toxicity.

Original languageEnglish (US)
Pages (from-to)232-235
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume27
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Topotecan
Neuroendocrine Tumors
Neutropenia
Islet Cell Adenoma
Carcinoid Tumor
Antineoplastic Agents
Appointments and Schedules
Survival
Population
Neoplasms

Keywords

  • Carcinoid tumor
  • Islet cell tumor
  • Neuroendocrine tumors
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Topotecan in patients with advanced neuroendocrine tumors : A phase II study with significant hematologic toxicity. / Ansell, Stephen Maxted; Mahoney, Michelle R.; Green, Erin M.; Rubin, Joseph.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, No. 3, 06.2004, p. 232-235.

Research output: Contribution to journalArticle

@article{2775a1dd67374c5b9075598a880930fb,
title = "Topotecan in patients with advanced neuroendocrine tumors: A phase II study with significant hematologic toxicity",
abstract = "New agents with antitumor activity in neuroendocrine tumors are sorely needed. We therefore conducted a phase II study of topotecan (TOPA) 1.5 mg/m2/d for 5 days every 3 weeks in 22 patients with advanced carcinoid and islet cell tumors. Severe neutropenia in 8 of 11 patients (72{\%}) prompted a 30{\%} dose reduction of TOPA to 1.05 mg/m2 for the final 11 patients enrolled. No objective responses were observed. Eighteen patients have progressed and 14 have died. The median time to progression was 4.2 months (95{\%} CI: 2.9-6.5) and the median survival was 1.9 years (95{\%} CI: 0.63-2.3). Hematologic adverse events were significant, with 16 of 22 patients developing grade IV neutropenia; however, there were no septic deaths. Nonhematologic adverse events were infrequent and were not dose limiting. In conclusion, further studies of this schedule of TOPA in this patient population are not recommended due to the lack of tumor response and significant hematologic toxicity.",
keywords = "Carcinoid tumor, Islet cell tumor, Neuroendocrine tumors, Topotecan",
author = "Ansell, {Stephen Maxted} and Mahoney, {Michelle R.} and Green, {Erin M.} and Joseph Rubin",
year = "2004",
month = "6",
doi = "10.1097/01.COC.0000054535.19808.F4",
language = "English (US)",
volume = "27",
pages = "232--235",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Topotecan in patients with advanced neuroendocrine tumors

T2 - A phase II study with significant hematologic toxicity

AU - Ansell, Stephen Maxted

AU - Mahoney, Michelle R.

AU - Green, Erin M.

AU - Rubin, Joseph

PY - 2004/6

Y1 - 2004/6

N2 - New agents with antitumor activity in neuroendocrine tumors are sorely needed. We therefore conducted a phase II study of topotecan (TOPA) 1.5 mg/m2/d for 5 days every 3 weeks in 22 patients with advanced carcinoid and islet cell tumors. Severe neutropenia in 8 of 11 patients (72%) prompted a 30% dose reduction of TOPA to 1.05 mg/m2 for the final 11 patients enrolled. No objective responses were observed. Eighteen patients have progressed and 14 have died. The median time to progression was 4.2 months (95% CI: 2.9-6.5) and the median survival was 1.9 years (95% CI: 0.63-2.3). Hematologic adverse events were significant, with 16 of 22 patients developing grade IV neutropenia; however, there were no septic deaths. Nonhematologic adverse events were infrequent and were not dose limiting. In conclusion, further studies of this schedule of TOPA in this patient population are not recommended due to the lack of tumor response and significant hematologic toxicity.

AB - New agents with antitumor activity in neuroendocrine tumors are sorely needed. We therefore conducted a phase II study of topotecan (TOPA) 1.5 mg/m2/d for 5 days every 3 weeks in 22 patients with advanced carcinoid and islet cell tumors. Severe neutropenia in 8 of 11 patients (72%) prompted a 30% dose reduction of TOPA to 1.05 mg/m2 for the final 11 patients enrolled. No objective responses were observed. Eighteen patients have progressed and 14 have died. The median time to progression was 4.2 months (95% CI: 2.9-6.5) and the median survival was 1.9 years (95% CI: 0.63-2.3). Hematologic adverse events were significant, with 16 of 22 patients developing grade IV neutropenia; however, there were no septic deaths. Nonhematologic adverse events were infrequent and were not dose limiting. In conclusion, further studies of this schedule of TOPA in this patient population are not recommended due to the lack of tumor response and significant hematologic toxicity.

KW - Carcinoid tumor

KW - Islet cell tumor

KW - Neuroendocrine tumors

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=2942563741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942563741&partnerID=8YFLogxK

U2 - 10.1097/01.COC.0000054535.19808.F4

DO - 10.1097/01.COC.0000054535.19808.F4

M3 - Article

VL - 27

SP - 232

EP - 235

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -